Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

P 2008

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN et. al.

Basic information

Original name

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Name in Czech

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Authors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Lawrence DILLARD, Vinh TRAN, Zhenmin HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR, Douglas HOBBS, Paul KIRSCHMEIER and Rajat BANNERJI

Edition

Number: US 2008/0050384 A1, Publisher: United States Patent Office, Place of publication: USA, Owner's name: Schering Plough and Pharmacopeia, 2008

Other information

Language

English

Type of outcome

Patent

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Science

Keywords (in Czech)

kinases; pyrazolopyrimidine; inhibitor

Keywords in English

kinases; pyrazolopyrimidine; inhibitor

Abstract

ORIG CZ

V originále

The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compd. I alone or in combination with other therapeutic agents are claimed.

In Czech

viz Anotace

Citovat

@misc{838035,
   author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Doll, Ronald and Girijavallabhan, Viyyoor and Mallams, Alan and Alvarez, Carmen and Keertikar, Kartik and Rivera, Jocelyn and Chan, TinandYau and Madison, Vincent and Fischmann, Thierry and Dillard, Lawrence and Tran, Vinh and He, Zhenmin and James, Ray and Park, Haengsoon and Paradkar, Vidyadhar and Hobbs, Douglas and Kirschmeier, Paul and Bannerji, Rajat},
   keywords = {kinases; pyrazolopyrimidine; inhibitor},
   language = {eng},
   title = {Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors},
   year = {2008}
}

TY  - PAT
ID  - 838035
AU  - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Doll, Ronald - Girijavallabhan, Viyyoor - Mallams, Alan - Alvarez, Carmen - Keertikar, Kartik - Rivera, Jocelyn - Chan, Tin-Yau - Madison, Vincent - Fischmann, Thierry - Dillard, Lawrence - Tran, Vinh - He, Zhenmin - James, Ray - Park, Haengsoon - Paradkar, Vidyadhar - Hobbs, Douglas - Kirschmeier, Paul - Bannerji, Rajat
PY  - 2008
TI  - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
KW  - kinases
KW  - pyrazolopyrimidine
KW  - inhibitor
N2  - The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compd. I alone or in combination with other therapeutic agents are claimed.
ER  -

Detailed Information on Publication Record